Access expired on Wednesday, May 4, 2022
This content was originally shared by a registered user, but access has expired. Create a free account to gain permanent access to all PracticeUpdate content.
Already Have An Account? Log in Now
featured
FGFR3 Mutation vs P53 and KI-67 Expression for Prognosis of Invasive Bladder Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Urologic Oncology: Seminars and Original Investigations
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patients
Urol. Oncol 2022 Mar 01;40(3)110.e1-110.e9, LS Mertens, F Claps, R Mayr, PJ Bostrom, SF Shariat, EC Zwarthoff, JL Boormans, C Abas, GJLH van Leenders, S Götz, K Hippe, S Bertz, Y Neuzillet, J Sanders, A Broeks, D Peters, MS van der Heijden, MAS Jewett, R Stöhr, AR Zlotta, M Eckstein, Y Soorojebally, DKE van der Schoot, B Wullich, M Burger, W Otto, F Radvanyi, N Sirab, D Pouessel, TH van der Kwast, A Hartmann, Y Lotan, Y Allory, TCM Zuiverloon, BWG van RhijnFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.